| Literature DB >> 32904764 |
Xiuru Yang1, Zhi Chen1, Wan Zhao1, Chunxi Liu1, Xiaoxiao Qian1, Ming Zhang2, Guoying Wei1, Eakalak Khan3, Yun Hau Ng4, Yong Sik Ok5.
Abstract
Antibiotics are widely present in the envEntities:
Keywords: Advanced materials; Clean water and sanitation; Green and sustainable remediation; High-performance photocatalyst; Reaction mechanisms for photodegradation
Year: 2020 PMID: 32904764 PMCID: PMC7457966 DOI: 10.1016/j.cej.2020.126806
Source DB: PubMed Journal: Chem Eng J ISSN: 1385-8947 Impact factor: 13.273
Methods for antibiotic degradation or removal in water.
| Adsorption processes | Anionic surfactant sodium dodecyl sulfate (SDS) | Amoxicillin | Contact time: 40 min | Low removal capacities; difficult separation; | |
| KOH-modified biochar | Norfloxacin | Temperature: 15–35 °C | |||
| Graphene oxide/cellulose nanofibril hybrid aerogel | Doxycycline | Temperature: 25 °C | |||
| Pyrogenic carbonaceous materials | Ciprofloxacin | Contact time: 72 h | |||
| Clean and dried | Ibuprofen | pH 2.5 or 5 | |||
| Manure-derived biochars | Lincomycin | pH 6 or 10 | |||
| Lanthanum modified diatomite | Tetracycline antibiotics | Contact time: 24 h | |||
| Adsorption processes | Grape stalk | Ofloxacin | pH 4, 7, and 9 | Low removal capacities; difficult separation; | |
| Cleaned and dried | Tetracycline | Temperature: 15–35 °C | |||
| Spent mushroom substrate | Sulfamethyldiazine | Temperature: 15 °C | |||
| Coagulation | Amino-acid-modified-chitosan flocculants | Norfloxacin | Temperature: 25 °C | Antibiotics cannot be completely removed and secondary pollution occurs readily | |
| Ozonation | Ozone | Amoxicillin | Neutral pH | Demands high equipment and energy costs | |
| Ozone/zero-valent iron | Flumequine | Contact time: 1h | |||
| Ozonation | Medium-high frequency ultrasound and ozone | Amoxicillin | Medium-high ultrasonic frequency waves: 575, 861, 1141 kHz | Demands high equipment and energy costs | |
| Ozone | Flumequine | Contact time: 6 min | |||
| Ozone | Ofloxacin | Temperature: 25 °C | |||
| Multistage ozone and biological treatment system | Amoxicillin | Temperature: 25 °C | Complex; high operating costs; continuous use is impractical | ||
| Chemical coagulation and microfiltration | Ibuprofen | Different doses of ZnO nanoparticles: 0.5, 0.7, 1.0, 1.3, 1.5, 1.7 g/L | |||
| Electric coagulation and photo-electro-Fenton process | Metronidazole | pH: 1, 3, 5, 7, 9 | |||
| Combined processes | A membrane bioreactor (MBR) integrated with solar Fenton oxidation | Sulfamethoxazole | H2O2: 20–100 mg/L | Complex; high operating costs; impracticability in continuous use | |
| Integrated adsorption-membrane filtration process | Norfloxacin | pH: 7 | |||
| Ultraviolet, chlorination, ozone disinfection | Antibiotic resistance genes | Chlorine concentrations: 2–32 mg/L | |||
| Adsorptive magnetic ion exchange resin | Sulfamethoxazole | Contact time: 30 min | |||
| Nanofiltration and chlorination | Sulfanilamide | Membrane effective area: 40.92 cm2 |
Fig. 1Number of search results of recent publications addressing the photocatalytic treatment of antibiotic residues using “photocatalytic” and “antibiotic treatment” as keywords (collected from the Web of Science Core Database: March 9, 2020).
Fig. 2Schematic representation of the semiconductor photocatalysis process [44]
Scheme 1Strategies for photocatalytic efficiency improvement.
Summary of previous studies using different strategies to improve photocatalytic degradation of antibiotics.
| Vacancies | BiOCl with abundant oxygen vacancies | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 87% optimum within 2 h | |
| Vacancies | Oxygen vacancy-rich mesoporous ZrO2 | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 80% optimum within 150 h | |
| Vacancies | BiOBr microspheres with oxygen vacancies | 10-W LED lamp (0.4 mW‧cm−2) | Tetracycline (TC) | Approximately 94% optimum within 90 min | |
| Vacancies | ZnWO4-x nanorods with oxygen vacancy | Hg lamp 300-W UV or 300-W Xe lamp (UV–Vis-NIR) | Tetracycline | Approximately 91% optimum within 90 min | |
| Vacancies | Bi2MoO6 with oxygen vacancy | 300-W Xe lamp | Ciprofloxacin | Approximately 55% optimum within 120 min | |
| Doping | Carbon-doped g-C3N4 | Sunlight | Tetracycline | Approximately 90% optimum within 90 min | |
| Doping | P-O co-doped g-C3N4 | 350-W Xe lamp (λ>420 nm) | Enrofloxacin10 mg/L | Approximately 90% within 80 min | |
| Doping | I and K co-doped g-C3N4 | 300-W Xe lamp (λ>420 nm) | Sulfamethoxazole | Approximately 99% optimum within 45 min | |
| Doping | Bi3+/g-C3N4 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 94% optimum within 30 min | |
| Doping | Cr3+/SrTiO3 | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 70% optimum within 60 min | |
| Doping | Fe2+/Fe3+ immobilized on TiO2/fly-ash cenospheres | 150-W tungsten halogen lamp (λ>420 nm) | Ciprofloxacin | Approximately 80% optimum within 60 min | |
| Doping | Ce3+ doped Bi2O3 | 300-W lamp (visible light) | Tetracycline | Approximately 89% optimum within 180 min | |
| Doping | Ti3+/N co-doped TiO2/diatomite granule | 150-W Xenon lamp with a UV light filter | Tetracycline | 92% optimum within 150 min | |
| Quantum dots | CQDs modified Bi2MoO6 | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | 88% optimum within 2h | |
| Quantum dots | CQDs/BiOBr microspheres | Visible light irradiation | Ciprofloxacin | Approximately 65% optimum within 180 min | |
| Quantum dots | TiO2/C-dots | Average intensity sunlight irradiation (72 klx) | Levofloxacin | Approximately 99% optimum within 90 min | |
| Quantum dots | ZnSe QDs/g-C3N4 | 300-W Xe lamp (λ>400 nm) | Ceftriaxone sodium | Approximately 80% optimum within 120 min | |
| Quantum dots | Ag2O/TiO2 quantum dots | 400-W halogen bulb (similar to sunlight) | Levofloxacin | Approximately 81% optimum within 90 min | |
| Quantum dots | CQDs/BiOI | 300-W Xe lamp (λ>400 nm) | Tetracycline | Approximately 70% optimum within 120 min | |
| Quantum dots | CQDs/BiOBr | 300-W Xe lamp (λ>400 nm) | Tetracycline | Approximately 60% optimum within 120 min | |
| Quantum dots | MoS2 modified Zn-AgIn5S8 quantum dots | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 74% optimum within 4 min | |
| Quantum dots | 3D ZnS-RGO nanospheres | 300-W Hg vapor lamp | Norfloxacin | 92% optimum within 4h | |
| Phase junction | Porous core–shell homojunction | UV lamp (254 nm, 90 W, Philips) | Tetracycline hydrochloride | Approximately 81% within 300 min | |
| Facet junction | CaCu3Ti4O12 | 300-W Xe lamp | Tetracycline | Approximately 99% within 50 min | |
| Facet junction | AgBr tetradecahedrons with co-exposed (1 0 0) and (1 1 1) facets | 500-W halogen tungsten lamp (λ>420 nm) | Sulfadiazine | Approximately 90% optimum within 90 min | |
| Schottky heterojunction | Ag/Ag2MoO4 | 500-W Xe lamp (λ>420 nm) | Ciprofloxacin | Approximately 99% optimum within 60 min | |
| Schottky heterojunction | Ag/TiO2 (hollow nanosphere) | 125-W high-pressure Hg lamp, (λ>435.8 nm) | Metronidazole | Approximately 95% optimum within 120 min | |
| Schottky heterojunction | Bi/BiOBr (nano-flowers) | 300-W Xe lamp (λ>420 nm) | Tetracycline hydrochloride Ciprofloxacin and Doxycycline | Approximately 100% optimum within 30 min | |
| Schottky heterojunction | BiOCl-Ag (2D) | 200-W Xe arc lamp (λ<420 nm) | Sulfonamides | Approximately 80% optimum within 5h | |
| Schottky heterojunction | Ag/Bi3O4Cl | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 94% optimum within 120 min | |
| Schottky heterojunction | Ag/CCN | 300-W Xe lamp (λ>420 nm) | Tetracycline | 75% optimum within 15 min | |
| Schottky heterojunction | Pt/g-C3N4 | 300-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 84% optimum within 40 min | |
| Schottky heterojunction | Bi (Spheres)/g-C3N4 | 300-W Xe lamp (λ>420 nm) | Amoxicillin | Approximately 5% optimum within 4 h | |
| Schottky heterojunction | W-doped BaTiO3 | Visible light irradiation | Tetracycline | Approximately 80% optimum within 3h | |
| Schottky heterojunction | Fe, Co, Ni, Fe-Co-, and Fe-Ni-doped ZnO | 300-W Xe lamp (λ=365 nm) | Oxytetracycline | Approximately 87% optimum within 2h | |
| Schottky heterojunction | Pt/Bi/TiO2 | 300-W halogen-tungsten lamp (λ>420 nm) | Amoxicillin | Approximately 87% optimum within 2h | |
| Schottky heterojunction | Au/Pt/g-C3N4 | 500-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 90% optimum within 3h | |
| Schottky heterojunction | 0D Bi nanodots/2D Bi3NbO7 nanosheets | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 86% optimum within 120 min | |
| Type Ⅱ heterojunction | AgI/BiVO4 | 300-W Xe lamp (λ>420 nm) | Tetracycline (TC) | Approximately 94% optimum within 1h | |
| Type Ⅱ heterojunction | 3D porous CdS/TiO2 | 300-W Xe lamp (λ>420 nm) | Tetracycline and oxytetracycline (OTC) | Approximately TC: 67% and OTC: 81% optimums within 50 min | |
| Type Ⅱ heterojunction | MgFe2O4/MoS2 | Radiation intensity: 47 mW/cm2 | Tetracycline | Approximately 92% optimum within 120 min | |
| Type Ⅱ heterojunction | ZnWO4-CdS | 300-W Xe lamp (λ>420 nm) | Ciprofloxacin | Approximately 90% optimum within 1h | |
| Type Ⅱ heterojunction | ZnO@ZnS nanorod | 500-W Xe lamp | Tetracycline | Approximately 80% within 140 min | |
| Type Ⅱ heterojunction | MoS2/PbBiO2I | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 80% optimum within 6h | |
| Type Ⅱ heterojunction | Bi2SiO5/Bi12SiO20 | 100-W high-pressure Hg lamp | Tetracycline | Approximately 79% optimum within 30 min | |
| Type Ⅱ heterojunction | SrTiO3/Fe2O3 | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 83% optimum within 140 min | |
| Type Ⅱ heterojunction | p-C3N4/f-BiOBr | 250-W Xe lamp (λ>400 nm) | Tetracycline | Approximately 94% optimum within 300 min | |
| Type Ⅱ heterojunction | Bi2O7Sn2-Bi7O9I3 | Halogen lamp as simulated solar light | Tetracycline | 80% optimum within 90 min | |
| Type Ⅱ heterojunction | NiFe2O4/Bi2O3 | 150-W xenon lamp (λ>420 nm) | Tetracycline | Approximately 91% optimum within 90 min | |
| Type Ⅱ heterojunction | BiVO4/rGO | 250-W Xe lamp (λ>420 nm) | Tetracycline | 99% optimum within 90 min | |
| Type Ⅱ heterojunction | SrTiO3 nanocube coated CdS microsphere | 250-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 94% optimum within 120 min | |
| Type Ⅱ heterojunction | g-C3N4/BiPO4 | 250-W high-pressure Hg lamp | Ciprofloxacin | Approximately 97% optimum within 120 min | |
| Type Ⅱ heterojunction | g-C3N4/Ag3PO4 | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 67% optimum within 15 min | |
| Type Ⅱ heterojunction | In2S3/NaTaO3 | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 80% optimum within 180 min | |
| Type Ⅱ heterojunction | Polyaniline/Bi4O5Br2 | Visible light | Ciprofloxacin | CIP: 99% optimum within 50 min, TC: approximately 86% optimum within 240 min | |
| Type Ⅱ heterojunction | CdS nanoparticles/porous carbon polyhedrons | 300-W Xe lamp (λ>420 nm) | Cephalexin | Approximately 90% optimum within 90 min | |
| Type Ⅱ heterojunction | Microsphere-like In2S3/InVO4 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 71% optimum within 60 min. | |
| Type Ⅱ heterojunction | g-C3N4/Bi4O5Br2 | 300-W Xe arc lamp | Ciprofloxacin | Approximately 67% optimum within 150 min | |
| Type Ⅱ heterojunction | Bi2WO6/g-C3N4 | 300-W Xe lamp UV light | Ceftriaxone sodium | Approximately 94% optimum within 120 min | |
| Type Ⅱ heterojunction | Flower-root shaped Bi2O3/Bi2MoO6 | 500-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 70% optimum within 190 min | |
| Type Ⅱ heterojunction | Covalent triazine framework modified BiOBr nanoflake | 500-W Xe lamp | Tetracycline | Approximately TC: 90% and CIP: 60% optimums within 50 min | |
| Type Ⅱ heterojunction | mpg-C3N4 and Bi2WO6 nest-like structure | 300-W Xe lamp (λ>420 nm) | Tetracycline hydrochloride | Approximately 75% optimum within 120 min | |
| Type Ⅱ heterojunction | TiO2 nanoparticle/SnNb2O6 nanosheet heterojunctions | 500-W tungsten lamp | Tetracycline hydrochloride | Approximately 76% optimum within 240 min | |
| Type Ⅱ heterojunction | Bi4Ti3O12/BiOCl (2D/0D) composite | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 84% optimum within 150 min | |
| Type Ⅱ heterojunction | 2D-2D g-C3N4/Bi4O5Br2 | 300-W Xe lamp (λ>400 nm) | Ciprofloxacin | Approximately 50% optimum within 30 min | |
| Type Ⅱ heterojunction | 2D/2D Bi4Ti3O12/I-BiOCl | 350-W Xe arc lamp (λ>420 nm) | Ciprofloxacin | Approximately 90% optimum within 120 min | |
| Type Ⅱ heterojunction | Carbon-doped carbon nitride/Bi12O17Cl2 | 300-W Xe lamp (λ>420 nm) | Tetracycline | 94% optimum within 60 min | |
| Type Ⅱ heterojunction | CuBi2O4/CuO | Visible light | Metronidazole | 36% optimum within 120 min | |
| p-n heterojunction | p-n type BiOCl/titanium phosphate nanoplates | 300-W Xe lamp | Ciprofloxacin | Approximately 100% within 5 min | |
| p-n heterojunction | p-n type CoO/g-C3N4 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% within 60 min | |
| p-n heterojunction | p-n type Cu2O/SrTiO3 | 150-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 79% within 100 min | |
| p-n heterojunction | p-n type flower-like BiOCl/BiOCOOH p-n | 300-W Xe lamp simulated sunlight | Tetracycline | Approximately 80% within 60 min | |
| p-n heterojunction | p-n type Ag2O/g-C3N4 | 500-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 94% within 3h | |
| p-n heterojunction | p-n type Co3O4-C3N4 | Sunlight | Tetracycline | Approximately 97% within 180 min | |
| p-n heterojunction | p-n type 3D flower-like BiOBr/Bi2SiO5 | 300-W Xe lamp (λ>420 nm) | Tetracycline | 91% within 120 min | |
| p-n heterojunction | n-p type SnO2 nanoparticles/BiOI | 300-W Xe lamp (λ>420 nm) | Oxytetracycline hydrochloride | Approximately 94% optimum within 90 min | |
| p-n heterojunction | p-n type N-graphene QDs-BiOI/MnNb2O6 | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 87% optimum within 60 min | |
| p-n heterojunction | p-n type Fe3O4 quantum dots modified BiOCl/BiVO4 | 300-W Xe lamp (λ>420 nm) | Sulfamethoxazole (SMX, 5 mg/L), TC (20 mg/L), norfloxacin (NOR, 10 mg/L), and CIP (10 mg/L) | SMX: 91% within 90 min, TC: 87% within 30 min, NOR: 89% within 60 min, CIP: 87% within 90 min | |
| Double heterojunction | CDs/MoS2/TiO2 nanobelt | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 82% within 3h | |
| Double heterojunction | (g-C3N4)-ZnO/halloysite nanotubes (HNTs) | 350-W Xe arc lamp | Tetracycline | Approximately 87% optimum within 60 min | |
| Double heterojunction | Ultrathin g-C3N4 nanosheets coupled with amorphous Cu doped FeOOH nanoclusters as 2D/0D heterogeneous catalysts | 500-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% within 40 min | |
| Double heterojunction | 2D/2D/2D CoAl-LDH/g-C3N4/RGO ternary heterojunction | 300-W halogen lamp visible-light irradiation | Tetracycline | Approximately 100% optimum within 60 min | |
| Double heterojunction | Ag-AgVO3/g-C3N4 | 300-W Xe lamp (λ>410 nm) | Tetracycline | Approximately 84% optimum within 120 min | |
| Double heterojunction | ZnFe2O4/Ag/Ag3VO4 | Visible-light irradiation | Tetracycline | Approximately 60% within 10 min | |
| Double heterojunction | NiS and MoS2 nanosheet co-modified g-C3N4 ternary heterostructure | 250-W metal halide lamp (λ>400 nm) | Tetracycline | Approximately CIP: 71% and TC: 96% optimums, within 120 min | |
| Double heterojunction | AgCl/Ag3PO4/ g-C3N4 | Visible-light irradiation (λ>400 nm) | Sulfamethoxazole | Approximately 100% optimum within 90 min | |
| Double heterojunction | 3D Ag3PO4/TiO2@MoS2 | 800-W Xe arc lamp | OTC 5 mg/L | Approximately OTC: 75%, ENR: 92% within 10 min | |
| Double heterojunction | Bi2O3/BiOCl supported on graphene sand (BO/BOC/GSC) composite (BO/BOC/CT) | Solar light intensity (35 × 103 ± 1000 lx) | Oxytetracycline | BO/BOC/GSC: approximately 90% for AMP and OTC | |
| Double heterojunction | Core-shell structured Fe3O4@SiO2@CdS | 1000-W tungsten-halide lamp (Philips) (λ>420 nm) | Tetracycline | Approximately 80% optimum within 21 min | |
| Double heterojunction | RGO-CdS/ZnS | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% optimum in 60 min | |
| Double heterojunction | TiO2/Bi2WO6/carbon fibers | 300-W Xe lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 95% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme beta-Bi2O3@g-C3N4 core/shell nanocomposite | 250-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 80% optimum within 50 min | |
| Z-scheme heterojunction | Z-scheme WO3-g-C3N4 | 300-W Xe arc lamp (1.5 AM solar simulator) | Sulfamethoxazole | Approximately 92% optimum within 4h | |
| Z-scheme heterojunction | Z-scheme AgI nanoparticle-sensitized Bi5O7I microspheres | 300-W Xe lamp | TC (20 mg/L), DTC (10 mg/L), OTC (10 mg/L), or CIP (10 mg/L) | Approximately TC: 95%, DTC: 90%, OTC: 80% and CIP: 90% optimums within 40 min | |
| Z-scheme heterojunction | Z-scheme CdTe/TiO2 | 400-W halogen lamp (λ>400 nm) | Tetracycline hydrochloride | Approximately 78% optimum within 30 min | |
| Z-scheme heterojunction | Type II AgI/CuBi2O4 | 300-W Xe lamp | Tetracycline | Approximately Type II catalyst: 80% and Z-scheme catalyst: 90% optimums within 30 min | |
| Z-scheme heterojunction | Z-scheme mesoporous Sn3O4 nanoclusters/g-C3N4 nanosheets | 500-W Xe lamp | Tetracycline hydrochloride | Approximately 72% optimum within 120 min | |
| Z-scheme heterojunction | Z-scheme Bi3TaO7 QDs/g-C3N4 nanosheets (NSs) | LED lamp | CIP and CPX | Approximately CIP: 91%, CPX: 77% CPX within 120 min | |
| Z-scheme heterojunction | Z-scheme WO3 nanosheet/K+Ca2Nb3O10− ultrathin nanosheet | 250-W xenon lamp as simulated sunlight (no filters). | Tetracycline hydrochloride | Approximately 86% optimum within 120 min | |
| Z-scheme heterojunction | Z-scheme AgI/BiOBr | 300-W Xe lamp (λ>420 nm) | Ciprofloxacin | Approximately 91% optimum within 1h | |
| Z-scheme heterojunction | Z-scheme Ag3PO4/g-C3N4 | 300-W Xe lamp (λ>400 nm) | Sulfamethoxazole | Approximately 99% optimum within 90 min | |
| Z-scheme heterojunction | Z-scheme CdS-Au-BiVO4 (0 1 0) | 300-W Xe lamp (λ>420 nm) | Tetracycline | 91% optimum within 90 min | |
| Z-scheme heterojunction | Z-scheme BiVO4/Ag/Cu2O | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 91% optimum within 90 min | |
| Z-scheme heterojunction | Z-scheme ZnFe2O4/Ag/PEDOT | 250-W xenon lamp (1.8×105 lx) | Tetracycline | Approximately 72% optimum within 120 min | |
| Z-scheme heterojunction | Organic-inorganic Z-scheme PANI/Ag/Ag2MoO4 | 40-W UV tube (Phillips) | Ciprofloxacin | Approximately 100% optimum within 40 min | |
| Z-scheme heterojunction | Z-scheme (0 0 1) BiOCl-Au-CdS | 300-W Xe lamp (AM 1.5) | Sulfadiazine | Approximately 91% optimum within 4h | |
| Z-scheme heterojunction | Z-scheme iodine vacancy-rich BiOI/Ag@AgI | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 86% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme Ag2CO3/Ag/WO3 | 300-W Xe lamp (λ>420 nm) | CIP and TC | Approximately CIP: 84% and TC: 81% optimums within 90 min | |
| Z-scheme heterojunction | Z-scheme AgI/Ag/Bi3TaO7 | 300-W Xe lamp (visible light) | Sulfamethoxazole | Approximately 98% optimum within 100 min | |
| Z-scheme heterojunction | Z-scheme MIL-53(Fe)/Ag/g-C3N4 | Visible light | Clioquinol | 95% optimum within 100 min | |
| Z-scheme heterojunction | Z-scheme CeVO4/3D RGO aerogel/BiVO4 | 500-W Xe lamp | Tetracycline | Approximately 100% optimum within 60 min | |
| Z-scheme heterojunction | TCPP/rGO/Bi2WO6 | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 84% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme Ag3PO4/Bi2S3/Bi2O3 | 300-W Xe lamp | Sulfamethazine (SAZ) and cloxacillin (CLX) | Approximately SAZ: 99% and CLX: 90% optimums within 90 min | |
| Z-scheme heterojunction | RGO-Ag2O/TiO2 | 350-W Hg lamp (λless than356 nm), 300-W Xe arc lamp (visible light), 300-W infrared lamp, and 156-W APOLLO solar simulator | Tetracycline | 100% and approximately 100% optimums within 60 min, approximately 90% optimums within 120 min | |
| Z-scheme heterojunction | Z-scheme g-C3N4/Ag2CO3/graphene oxide | 300-W Xe lamp | Tetracycline | Approximately 82% optimum within 60 min | |
| Z-scheme heterojunction | Z-scheme nitrogen-doped graphene QDs-BiVO4/g-C3N4 | 250-W Xe lamp | Tetracycline | Approximately 91% optimum within 30 min | |
| Z-scheme heterojunction | Z-scheme graphitic carbon nitride (CN) and reduced graphene oxide (rGO) with AP | Both intense sunlight and weak indoor light irradiation | Norfloxacin | Approximately 100% optimum within 30 min and 85% optimum within 2h | |
| Z-scheme heterojunction | Z-scheme WO3/Fe3O4/g-C3N4 | 300-W Xe lamp | Tetracycline | 89% optimum within 120 min | |
| Z-scheme heterojunction | Z-scheme nitrogen-doped hollow mesoporous carbon spheres (N-HMCs) modified g-C3N4/Bi2O3 | 300-W Xe lamp | Tetracycline hydrochloride (TCH) and ciprofloxacin hydrochloride (CFH) | Approximately 90% and 80% optimum within 60 min | |
| Exposing active facets | Bi2O2(OH)(NO3) nanosheets with (0 0 1) active exposing facets | UV light irradiation | Tetracycline hydrochloride | Approximately 98% optimum within 25 min | |
| Exposing active facets | Ultrathin Bi2O2(OH)xCl2-x solid solution with exposed (0 0 1) facets | Visible light | Ciprofloxacin | Approximately 90% optimum within 150 min | |
| Exposing active facets | Nanosheet BiVO4 with oxygen vacancies and exposed (0 0 1) facets | 500-W Xe lamp without optical filters to simulate the sunlight | Oxytetracycline | Approximately 96% optimum within 2h | |
| Exposing active facets | Various well-defined Bi2WO6 crystals | 300-W Xe lamp | Ciprofloxacin | Approximately 70% optimum within 5h | |
| Exposing active facets | Doped BiOCl nanoplates | 300-W Xe lamp (λ>420 nm) | Tetracycline hydrochloride | Approximately 90% optimum within 100 min | |
| Exposing active facets | (0 0 1) Ag@NC-TiO2 square nanosheets | 350-W Xe arc lamp (λ>420 nm) | Ciprofloxacin | Approximately 97% optimum within 150 min | |
| Exposing active facets | TiO2@g-C3N4 core–shell quantum | Xe lamp irradiation. | Tetracycline | Approximately 100% optimum within less than 10 min | |
| Porous materials | Intercalate structure g-C3N4@ATP | 300-W Xe lamp (λ>420 nm) | Tetracycline | Approximately 90% optimum within 2h | |
| Porous materials | 3D hierarchical mesoporous BiOI | 1000-W tungsten halogen lamp | Tetracycline hydrochloride | Approximately 100% optimum within 37.5 or 101.5 min | |
| Porous materials | BiOI hollow microspheres | 300-W Xe lamp (λ>400 nm) | Tetracycline | 80% optimum within 120 min | |
| Porous materials | Ultra-thin Bi2MoO6 nanosheets | Sunlight | Ofloxacin | Approximately 71% optimum within 90 min | |
| Tailoring morphology | Rod-like SrV2O6 | 500-W tungsten lamp (λ>400 nm) | Metronidazole | 98% optimum within 60 min | |
| Tailoring morphology | TiO2 nanobelts | Simulative solar light | Amikacin | Approximately 70% optimum within 150 min | |
| Tailoring morphology | ZnO Nanotubes | 300-W Xe lamp (AM1.5 filter (1000 Wm−2)) | Ciprofloxacin | Approximately 12% optimum within 2h | |
| Tailoring morphology | Bi5FeTi3O15 | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 99% optimum within 1h | |
| Tailoring morphology | Navel-like Bi2WO6 hierarchical microspheres | UV light irradiation (λ=365 nm) | Norfloxacin | Approximately 67% optimum within 8h | |
| Tailoring morphology | spearhead-like g-C3N4 | Xe lamp | Tetracycline | Approximately 70% optimum within 180 min | |
| 3D aerogel | g-C3N4@CA/B-PET | Artificial solar light | Sulfaquinoxaline sodium | Approximately 100% optimum within 60 min | |
| 3D aerogel | BiVO4/3D RGO aerogel/CeVO4 | 500-W Xe lamp | Tetracycline | Approximately 90% optimum within 120 min | |
| 3D aerogel | 3D MoS2 nanosheets/graphene aerogel | 300-W Xe lamp | Tetracycline hydrochloride | Approximately 10% optimum within 75 min |
Fig. 3Schematic of the OV-induced photocatalytic process on ZnWO4-x[54]
Fig. 4(a) UV–vis diffuse reflectance spectra of a) 1) raw TiO2 (5 0 0), and N-TiO2 (T) samples prepared at 2) 450, 3) 500, 4) 550, 5) 600, 6) 700 and 7) 800 °C [247], (b) diffuse reflection spectra (DRS) curves of undoped and doped TDHG [63], Inset: Photographs of TDHG, N-TDHG, b -TDHG and b/N-TDHG photocatalysts.
Fig. 5(a) Light absorption curves [252] and (b) photocatalytic mechanisms of CQD/TNT photocatalyst [253]
Fig. 6Mott-Schottky curves on (a) CN and (b) PN-2; (c and d) schematic of carrier migration at the p-n homojunction [201]
Fig. 7(a) Photodegradation of TC by the as-synthesized plasmonic Ag/Bi3O4Cl under visible irradiation, (b) possible photocatalytic mechanisms on the Ag/Bi3O4Cl samples [79], (c) photocatalytic kinetics of prepared g-C3N4, Pt/g-C3N4, Au/g-C3N4, and Au/Pt/g-C3N4 nanocomposites [86] (d) schematic of the g-C3N4 photoinduced charge transport [284]
Fig. 8Preparation process for g-C3N4/Bi4O5Br2 nanocomposites [114]
Fig. 9(a) Roadmap of Z-scheme photocatalytic system evolution [293]; (b) suggested photoinduced charge transport on g-C3N4(60)/TNTAs [296]
Fig. 10Photocatalytic degradation mechanisms of CR and TC by a ternary LDH/CN/RGO heterostructure [130]
Fig. 11Synthesis of BiVO4/RGO/CeVO4 heterostructures [159]